X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs AUROBINDO PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH AUROBINDO PHARMA PANACEA BIOTECH/
AUROBINDO PHARMA
 
P/E (TTM) x -20.0 15.7 - View Chart
P/BV x 2.8 3.9 71.3% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 PANACEA BIOTECH   AUROBINDO PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
AUROBINDO PHARMA
Mar-17
PANACEA BIOTECH/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs149895 16.6%   
Low Rs82622 13.2%   
Sales per share (Unadj.) Rs84.1254.6 33.1%  
Earnings per share (Unadj.) Rs-18.339.3 -46.6%  
Cash flow per share (Unadj.) Rs-6.746.6 -14.4%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs83.7160.0 52.3%  
Shares outstanding (eoy) m61.25585.88 10.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.43.0 46.1%   
Avg P/E ratio x-6.319.3 -32.7%  
P/CF ratio (eoy) x-17.216.3 -105.9%  
Price / Book Value ratio x1.44.7 29.1%  
Dividend payout %06.4 0.0%   
Avg Mkt Cap Rs m7,074444,390 1.6%   
No. of employees `0002.814.0 19.7%   
Total wages/salary Rs m1,44917,678 8.2%   
Avg. sales/employee Rs Th1,874.110,667.8 17.6%   
Avg. wages/employee Rs Th527.01,264.3 41.7%   
Avg. net profit/employee Rs Th-407.71,645.8 -24.8%   
INCOME DATA
Net Sales Rs m5,154149,157 3.5%  
Other income Rs m1001,159 8.6%   
Total revenues Rs m5,254150,316 3.5%   
Gross profit Rs m-76634,343 -2.2%  
Depreciation Rs m7114,276 16.6%   
Interest Rs m1,503667 225.3%   
Profit before tax Rs m-2,88130,558 -9.4%   
Minority Interest Rs m1150 21.5%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m177,597 0.2%   
Profit after tax Rs m-1,12123,012 -4.9%  
Gross profit margin %-14.923.0 -64.6%  
Effective tax rate %-0.624.9 -2.3%   
Net profit margin %-21.815.4 -141.0%  
BALANCE SHEET DATA
Current assets Rs m3,81092,062 4.1%   
Current liabilities Rs m8,36566,223 12.6%   
Net working cap to sales %-88.417.3 -510.2%  
Current ratio x0.51.4 32.8%  
Inventory Days Days156106 146.9%  
Debtors Days Days6768 99.4%  
Net fixed assets Rs m14,48062,919 23.0%   
Share capital Rs m61586 10.5%   
"Free" reserves Rs m90393,133 1.0%   
Net worth Rs m5,12793,719 5.5%   
Long term debt Rs m5,8321,814 321.5%   
Total assets Rs m19,433162,494 12.0%  
Interest coverage x-0.946.8 -2.0%   
Debt to equity ratio x1.10 5,876.3%  
Sales to assets ratio x0.30.9 28.9%   
Return on assets %2.014.6 13.5%  
Return on equity %-21.924.6 -89.1%  
Return on capital %3.632.7 11.1%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,53975,838 2.0%   
Fx outflow Rs m94230,224 3.1%   
Net fx Rs m59745,613 1.3%   
CASH FLOW
From Operations Rs m59932,786 1.8%  
From Investments Rs m-438-17,870 2.5%  
From Financial Activity Rs m-303-19,153 1.6%  
Net Cashflow Rs m-141-4,239 3.3%  

Share Holding

Indian Promoters % 74.5 54.1 137.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 8.0 7.5%  
FIIs % 1.3 27.7 4.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.2 231.4%  
Shareholders   10,259 69,601 14.7%  
Pledged promoter(s) holding % 35.1 8.6 409.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare PANACEA BIOTECH With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 207 Points Higher; Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade in the green during the closing hours of the trading session and ended the day on a positive note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Is Franklin India Smaller Companies Fund Worth Your Money(Outside View)

Aug 2, 2018

Although positioned as a small cap fund, Franklin India Smaller Companies Fund has been investing a significant portion of its assets in mid-caps along with a nominal exposure to large caps.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 14, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - TORRENT PHARMA COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS